Cancer remains one of the most deadly diseases globally, but carbon-based nanomaterials have the potential to revolutionize cancer diagnosis and therapy. Advances in nanotechnology and a better understanding of tumor microenvironments have contributed to novel nanotargeting routes that may bring new hope to cancer patients. Several low-dimensional carbon-based nanomaterials have shown promising preclinical results; as such, low-dimensional carbon dots (CDs) and their derivatives are considered up-and-coming candidates for cancer treatment. The unique properties of carbon-based nanomaterials are high surface area to volume ratio, chemical inertness, biocompatibility, and low cytotoxicity. It makes them well suited for delivering chemotherapeutics in cancer treatment and diagnosis. Recent studies have shown that the CDs are potential applicants in biomedical sciences, both as nanocarriers and nanotransducers. This review covers the most commonly used CD nanoparticles in nanomedicines intended for the early diagnosis and therapy of cancer.

In this study, we developed NIR-light responsive poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) by incorporating the ICG dye for the local delivery of small-molecule drugs and therapeutics.

Background: The news regarding the successful treatment of uncured diseases is extremely exciting. Recently, the study of stem cells has been widely considered. Objectives: The stem cells have the potential to be converted to all specialized functional cells. Methods: Advances in cell engineering and genetic reprogramming of the stem cells have contributed to novel approaches that may bring hope to HIV and cancer patients. Results: In this regard, HIV patients recently received a stem-cell transplant that replaced their white blood cells with HIV-resistant versions (obtained from stem cells). However, only a few clinically successful approaches are available on new stem cells. Conclusion: This review includes two parts; in the first section, the reader can obtain a basic idea about stem cells, whereas the second part emphasizes new opportunities and directions in translating stem cells basic research to the clinical applications.